TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines

Published
07 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
€2.00
49.0% undervalued intrinsic discount
15 Aug
€1.02
Loading
1Y
2.0%
7D
1.5%

Author's Valuation

€2.0

49.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 44%

Shared on24 Apr 25
Fair value Decreased 31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 156%

Shared on09 Apr 25
Fair value Decreased 44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.